Three areas of expertise under one roof to lead projects to success
Read More
Your pharmaceutical exploitant to market your products to French patients
Read More
Your distributor for in house storage under qualified temperature conditions & product dispatch
Read More
Your manufacturer to put packaging in compliance with local requirements
Read More
Exploitant, Distributor, Manufacturer & Importer : Ensuring access for medicines to the French market from Early Access Program to Post-Market Approval.
Cevidra has the status of pharmaceutical exploitant for the marketing of medicinal products in France.
Read More
Cevidra is the owner and distributor of the products it markets and can also act on behalf of MAH to store & distribute their products.
Read More
Cevidra performs batch release of manufactured or imported medicinal products.
Read MoreCevidra proposes a unique & integrated offer unrivaled in France by leveraging its complementary activities to bring products under ATU (Temporary Use Authorization) or MA (Marketing Authorization) to the French market with a strong expertise in medicines for rare or orphan diseases.
CEVIDRA is dedicated daily to its partner & committed to improving the trust of suppliers, patients, families and Health Care Professionals through a culture oriented towards 4 key values, each carried by all of our employees :
« Cevidra is a family-owned pharmaceutical company with a clear focus on top-line projects. We are faster, better, and more experienced than anyone else in managing complete processes for Early Access or Compassionate Use in France. We do this by optimizing the regulatory and marketing strategies, we manage internally the manufacturing from labelling to batch release as well as the distribution and sales with hospitals and retail pharmacies. We deliver measurable revenue on projects and market growth for our partners from Europe and others regions. »
Stéphane Destaing, President of CEVIDRA
MabDesign is a French association of the industrial sector of biomedicines. Created in 2014 in response to the call for projects “Filière Industriel Stratégique d’Avenir”, and in response to a proposal from the previous CSF Bioproduction, MabDesign aims to structure the industrial sector of biomedicines in France from its R&D phases to marketing, via bioproduction […]
Back to London in March 2022, Cevidra team will attend to the 8th RWE, Market Access, Pricing & Reimbursement Congress co-located with the Expanded Access Programmes Global Congress. The conferences will focus on critical issues that shape the future of European Market Access. We will meet with stakeholders from industry (government, pharmaceuticals, biotech non-profits, research […]
The Company CEVIDRA is a family-owned pharmaceutical company specializing in the marketing of high added value drugs and which wants to make innovative therapies accessible to thousands of French patients suffering from rare diseases. Cevidra offers unique and comprehensive support in BtoB and covers activities related to the operation, manufacturing, storage and distribution of products. […]
Our CEO, Stéphane Destaing accompanied by his project managers, Justine Gallet and Loïc Fiévet, will take part in several London congresses for BtoB meetings. Feel free to reach out. Notice: JavaScript is required for this content.
Cevidra brings in biotech expert profile to drive the advent of next-generation medicines to the French market We’re pleased to announce Loïc FIEVET, PharmD, PhD, will serve as a new Deputy Qualified Person of Cevidra company through its next chapter, as it aims to bring new #EarlyAccess medicines to French patients. After a first milestone in clinical trial bioproduction sites as QC manager, notably at EFS in collaboration with the CHU de Toulouse, he then advised multiple biotechnology companies as […]
Cevidra will attend to the Bio Digital Congress Benefits of a digital event Through the pandemic and the pivot to digital, ...
Cevidra will attend to the Bio Digital Congress Benefits of a digital event Through the pandemic and the pivot to digital, ...
Laboratoire Cevidra
